With close ties by the principals to University of California Irvine - and currently resident in JLABS San Diego, GlyTR Therapeutics is structured around development of a novel immunotherapy platform technology uniquely targeting highly diverse cancer types, ranging from breast cancer to leukemia - designed to offer immunotherapeutic anti-cancer molecules and cells useing bi-specific molecules to trigger the body's immune system to release immune cells for killing of cancer cells effectively enabling treatment of abnormal glycans in cancer. With the potential to overcome many of the shortcomings of current immunotherapies by binding to a never-before targeted tumor associated carbohydrate antigens (targets) that are common to many cancer types, The firm's breakthrough patented immunotherapy technology is designed to unleash the power of the immune system to kill cancer in a highly targeted manner. Providing significant advantages over other types of therapies, the Glytr approach works on multiple types of cancers including blood and solid tumors offering the potential to become an entirely new class of immunotherapeutic drugs.
